1084 related articles for article (PubMed ID: 9002492)
1. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.
Classen DC; Pestotnik SL; Evans RS; Lloyd JF; Burke JP
JAMA; 1997 Jan 22-29; 277(4):301-6. PubMed ID: 9002492
[TBL] [Abstract][Full Text] [Related]
2. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality.
Pittet D; Tarara D; Wenzel RP
JAMA; 1994 May; 271(20):1598-601. PubMed ID: 8182812
[TBL] [Abstract][Full Text] [Related]
3. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.
Bates DW; Spell N; Cullen DJ; Burdick E; Laird N; Petersen LA; Small SD; Sweitzer BJ; Leape LL
JAMA; 1997 Jan 22-29; 277(4):307-11. PubMed ID: 9002493
[TBL] [Abstract][Full Text] [Related]
4. Healthcare-associated Staphylococcus aureus bloodstream infection: length of stay, attributable mortality, and additional direct costs.
Primo MG; Guilarde AO; Martelli CM; Batista LJ; Turchi MD
Braz J Infect Dis; 2012; 16(6):503-9. PubMed ID: 23158266
[TBL] [Abstract][Full Text] [Related]
5. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay.
Oderda GM; Said Q; Evans RS; Stoddard GJ; Lloyd J; Jackson K; Rublee D; Samore MH
Ann Pharmacother; 2007 Mar; 41(3):400-6. PubMed ID: 17341537
[TBL] [Abstract][Full Text] [Related]
6. Using a hospital information system to assess the effects of adverse drug events.
Evans RS; Classen DC; Stevens LE; Pestotnik SL; Gardner RM; Lloyd JF; Burke JP
Proc Annu Symp Comput Appl Med Care; 1993; ():161-5. PubMed ID: 8130454
[TBL] [Abstract][Full Text] [Related]
7. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital.
Warren DK; Quadir WW; Hollenbeak CS; Elward AM; Cox MJ; Fraser VJ
Crit Care Med; 2006 Aug; 34(8):2084-9. PubMed ID: 16763511
[TBL] [Abstract][Full Text] [Related]
8. Costs of intravenous adverse drug events in academic and nonacademic intensive care units.
Nuckols TK; Paddock SM; Bower AG; Rothschild JM; Fairbanks RJ; Carlson B; Panzer RJ; Hilborne LH
Med Care; 2008 Jan; 46(1):17-24. PubMed ID: 18162851
[TBL] [Abstract][Full Text] [Related]
9. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs.
Kirkland KB; Briggs JP; Trivette SL; Wilkinson WE; Sexton DJ
Infect Control Hosp Epidemiol; 1999 Nov; 20(11):725-30. PubMed ID: 10580621
[TBL] [Abstract][Full Text] [Related]
10. Computerized surveillance of adverse drug events in hospital patients.
Classen DC; Pestotnik SL; Evans RS; Burke JP
JAMA; 1991 Nov; 266(20):2847-51. PubMed ID: 1942452
[TBL] [Abstract][Full Text] [Related]
11. Hospital-acquired, laboratory-confirmed bloodstream infection: increased hospital stay and direct costs.
Orsi GB; Di Stefano L; Noah N
Infect Control Hosp Epidemiol; 2002 Apr; 23(4):190-7. PubMed ID: 12002233
[TBL] [Abstract][Full Text] [Related]
12. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center.
Warren DK; Shukla SJ; Olsen MA; Kollef MH; Hollenbeak CS; Cox MJ; Cohen MM; Fraser VJ
Crit Care Med; 2003 May; 31(5):1312-7. PubMed ID: 12771596
[TBL] [Abstract][Full Text] [Related]
13. Costs attributable to healthcare-acquired infection in hospitalized adults and a comparison of economic methods.
Roberts RR; Scott RD; Hota B; Kampe LM; Abbasi F; Schabowski S; Ahmad I; Ciavarella GG; Cordell R; Solomon SL; Hagtvedt R; Weinstein RA
Med Care; 2010 Nov; 48(11):1026-35. PubMed ID: 20940650
[TBL] [Abstract][Full Text] [Related]
14. Hospital costs, length of stay and mortality attributable to invasive scedosporiosis in haematology patients.
Heng SC; Slavin MA; Chen SC; Heath CH; Nguyen Q; Billah B; Nation RL; Kong DC
J Antimicrob Chemother; 2012 Sep; 67(9):2274-82. PubMed ID: 22643193
[TBL] [Abstract][Full Text] [Related]
15. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance.
Morgan J; Meltzer MI; Plikaytis BD; Sofair AN; Huie-White S; Wilcox S; Harrison LH; Seaberg EC; Hajjeh RA; Teutsch SM
Infect Control Hosp Epidemiol; 2005 Jun; 26(6):540-7. PubMed ID: 16018429
[TBL] [Abstract][Full Text] [Related]
16. Costs of adverse drug events in German hospitals--a microcosting study.
Rottenkolber D; Hasford J; Stausberg J
Value Health; 2012; 15(6):868-75. PubMed ID: 22999137
[TBL] [Abstract][Full Text] [Related]
17. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals.
Kim T; Oh PI; Simor AE
Infect Control Hosp Epidemiol; 2001 Feb; 22(2):99-104. PubMed ID: 11232886
[TBL] [Abstract][Full Text] [Related]
18. Impact of nosocomial infections on medical costs, hospital stay, and outcome in hospitalized patients.
Sheng WH; Chie WC; Chen YC; Hung CC; Wang JT; Chang SC
J Formos Med Assoc; 2005 May; 104(5):318-26. PubMed ID: 15959598
[TBL] [Abstract][Full Text] [Related]
19. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit.
Digiovine B; Chenoweth C; Watts C; Higgins M
Am J Respir Crit Care Med; 1999 Sep; 160(3):976-81. PubMed ID: 10471627
[TBL] [Abstract][Full Text] [Related]
20. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use.
Page RL; Ruscin JM
Am J Geriatr Pharmacother; 2006 Dec; 4(4):297-305. PubMed ID: 17296535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
